Alexion Pharmaceuticals, Inc.
alexion.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
253
Active
42
Phase 3
60
Total enrollment
40,313
Pipeline matrix
Showing 23 of 23 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ravulizumab | — | 31 | |||||
| Acoramidis | — | — | — | — | 2 | ||
| Prednisone/Prednisolone | — | — | — | — | — | 1 | |
| Danicopan | — | — | 22 | ||||
| ALXN1850 | — | — | — | — | 4 | ||
| CAEL-101 | — | — | — | — | 3 | ||
| cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | — | — | — | — | — | 2 | |
| asfotase alfa | — | 14 | |||||
| Gefurulimab | — | — | — | — | 2 | ||
| ALXN1720 | — | — | — | — | 2 | ||
| eneboparatide | — | — | — | — | — | 1 | |
| ALXN2220 | — | — | — | — | — | 1 | |
| Eculizumab | — | — | 37 | ||||
| ALXN2030 | — | — | — | — | 2 | ||
| ALXN1920 | — | — | — | — | 2 | ||
| ALXN2420 | — | — | — | — | — | 1 | |
| AZD0120 | — | — | — | — | — | 1 | |
| Tarperprumig | — | — | — | — | — | 1 | |
| ALXN2350 | — | — | — | — | — | 1 | |
| ALXN2230 | — | — | — | — | — | 1 | |
| Soliris/Ultomiris | — | — | — | — | — | 1 | |
| hLB-001 | — | — | — | — | — | 1 | |
| Ultomiris | — | — | — | — | — | 1 |
Next readouts
- 2024-11-15
- 2025-04-08
- 2025-05-10
- 2025-05-27
- 2025-07-09
- 2025-07-23
- 2025-10-09
- 2026-01-05
- 2026-01-06
- 2026-06-22
Top conditions
- Healthy47
- Paroxysmal Nocturnal Hemoglobinuria18
- Hypophosphatasia16
- Lysosomal Acid Lipase Deficiency12
- Wilson Disease10
- Generalized Myasthenia Gravis10
- PNH8
- Neuromyelitis Optica Spectrum Disorder7
Frequently asked questions about Alexion Pharmaceuticals, Inc.
- How many clinical trials does Alexion Pharmaceuticals, Inc. have on ClinicalTrials.gov?
- Alexion Pharmaceuticals, Inc. is listed as the lead sponsor on 253 clinical trials in ClinicalTrials.gov, 42 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Alexion Pharmaceuticals, Inc.'s trials are in Phase 3?
- 60 of Alexion Pharmaceuticals, Inc.'s trials are in Phase 3, spread across 23 active drug programs.
- What therapeutic areas does Alexion Pharmaceuticals, Inc. focus on?
- Alexion Pharmaceuticals, Inc.'s most-studied conditions on ClinicalTrials.gov are Healthy, Paroxysmal Nocturnal Hemoglobinuria, Hypophosphatasia, Lysosomal Acid Lipase Deficiency, Wilson Disease.
- When are Alexion Pharmaceuticals, Inc.'s next clinical trial readouts?
- Alexion Pharmaceuticals, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism”, expected around 2024-11-15.